Fresenius achieves record Q3 earnings - improves 2011 earnings outlook

Bad Homburg (ots) -

- Cross-reference: Press release including Group Key Figures is
available at http://ots.de/3VRdj -

Q1-3 2011:

- Sales EUR 12.1 billion,
+2% at actual rates, +5% in constant currency

- EBIT EUR 1,862 million,
+5% at actual rates, +9% in constant currency

- Net income EUR 565 million,
+14% at actual rates, +17% in constant currency

- Fresenius improves 2011 earnings1 outlook of 15% to 18% constant
currency growth to upper half of range
- Group earnings at single-quarter all-time high - EUR 202 million
net income(1), record 16% EBIT margin
- Fresenius Medical Care with further margin improvement and
strong earnings growth
- Fresenius Kabi with 3% organic sales growth over outstanding Q3
2010
- Fresenius Helios continues expansion in the German hospital
market - raises earnings guidance
- Fresenius Vamed with excellent order intake of EUR 171 million
in Q3

Ulf Mark Schneider, CEO of Fresenius, commented: "Fresenius had a
very strong third quarter. With a Group EBIT margin of 16% and net
income of ?202 million we reached new all-time highs. We improve our
2011 earnings outlook and expect to achieve the upper half of our 15%
to 18% target range. HELIOS? acquisitions of the private hospital
chain Damp and the maximum care hospital in Duisburg significantly
strengthen our presence in the German hospital market. This marks a
further step in our growth strategy, which combines organic growth
and acquisitions."

Group outlook 2011

Fresenius improves its 2011 earnings guidance and expects to
achieve constant currency net income growth in the upper half of the
15% to 18% range. Based on the sales growth of the first three
quarters, Fresenius now expects to increase sales by c. 6% in
constant currency.

The Group plans to invest approximately 5% of sales in property,
plant and equipment.

In 2011, the net debt/EBITDA ratio is expected to stay in the
range of 2.5 to 3.0. For calendar year 2012, Fresenius Medical Care's
and Fresenius Helios' recently announced entirely debt and cash
flow-financed acquisitions are not expected to cause Group leverage
to exceed that target range.

(1) Net income attributable to Fresenius SE & Co. KGaA; adjusted
for the effects of mark-to-market accounting of the Mandatory
Exchangeable Bonds (MEB) and the Contingent Value Rights (CVR)
related to the acquisition of APP Pharmaceuticals. Both are
non-cash items.

Contact:
Matthias Link
Corporate Communications

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg
Germany
T +49 6172 608-2872
F +49 6172 608-2294
Matthias.Link@fresenius.com
www.fresenius.com